De la faillibilité au serf-arbitre : le tournant herméneutique de Paul Ricoeur

Ce mémoire a pour but de montrer que le premier tournant herméneutique de Paul Ricœur en 1960 gravite essentiellement autour de la problématique de la volonté mauvaise. Nous soutenons autrement dit que Ricœur a initialement donné une tournure herméneutique à sa philosophie pour penser le serf-arbitre, c’est-à-dire pour penser la liberté captive d’elle-même. Afin de rendre compte adéquatement de ce tournant, notre attention sera principalement dirigée vers le deuxième tome de la Philosophie de la volonté de Ricœur, Finitude et culpabilité. Notre question se pose ainsi : comment et pourquoi, dans une problématique du mal, Ricœur entame-t-il son tournant herméneutique? Pour y répondre, nous expliciterons le parcours de Ricœur allant de L’homme faillible à La symbolique du mal. Nous verrons dans un premier temps que si le philosophe arrive à thématiser le concept de faillibilité à partir d’une ontologie de la disproportion, si la réflexion a accès à la possibilité du mal, il n’en ira pas de même pour le noème inintelligible que constitue le mal moral. Afin de penser la faute, nous verrons que Ricœur se tournera vers l’herméneutique en se mettant à l’écoute du langage de l’aveu. Ainsi, dans la deuxième partie de notre mémoire, nous expliciterons les trois moments de compréhension (phénoménologique, herméneutique et réflexif) propre à l’herméneutique philosophique de Ricœur de 1960.

HJV Hemochromatosis, Iron Overload, and Hypogonadism in a Brazilian Man: Treatment with Phlebotomy and Deferasirox

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil[2008/54131-0]

Engineering from within: Habibie the man and Indonesia’s reformasi

Bacharuddin Jusuf Habibie, even now, remains a deeply puzzling figure for scholars and commentators concerned with matters Indonesian, Western and Indonesian alike.

HPV6b virus like particles are potent immunogens without adjuvant in man

Subjects with genital warts were immunized three times or more with HPV6b VLPs without adjuvant. All immunized subjects had DTH to HPV6b L1 protein. Of 32 subjects, nine had HPV6b specific antibody prior to immunization and 22 acquired antibody with immunization. VLP specific antibody increased following a single immunization in 6 of 8 subjects with low level antibody at recruitment. Complete regression of genital warts was observed in 25 of 33 evaluable subjects over the 20-week observation period. We conclude that immunization with HPV6b L1 VLPs without adjuvant induces immunity to the L1 protein epitopes recognised during natural infection, and may accelerate regression of warts. (C) 2000 Elsevier Science Ltd. All rights reserved.

Multiple conformational epitopes are recognized by natural and induced immunity to the E7 protein of human papilloma virus type 16 in man

The reactivity of sera from patients with cervical cancer with the E7 protein of human papilloma virus type 16 (HPV16) was estimated using a novel non-radioactive immunoprecipitation assay and four established protein-and peptide-based immunoassays. Six of 14 sera from patients with cervical cancer and 1 of 10 sera from healthy laboratory staff showed repeated reactivity with E7 in at least one assay. Four of the 7 reactive sera were consistently reactive in more than one assay, but only one was reactive in all four assays. Following immunization with E7, 2 of 5 patients with cervical cancer had increased E7-specific reactivity, measurable in one or more assays. No single assay was particularly sensitive for E7 reactivity, or predictive of cervical cancer. Mapping of E7 reactivity to specific E7 peptides was unsuccessful, suggesting that natural or induced E7 reactivity in human serum is commonly directed to conformational epitopes of E7, These results suggest that each assay employed with is study measures a different aspect of E7 reactivity, and that various reactivities to E7 may manifest following HPV infection or immunization. This finding is of significance for monitoring of E7 immunotherapy and for serological screening for cervical cancer. Copyright (C) 2000 S.Karger, AG. Basel.